EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer

Si Shi, Miaoyan Wei, Nan Du, Jialin Li, Boyue Han, Wei Wang, Xin Hu, Fei Luo, Jin Xu, Xianjun Yu

Cancer Cell · 2026-10 · 44 (10) · 2100-2107.e2

DOI: 10.1016/j.ccell.2026.08.012 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026-10. Verfasst von Si Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan U…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)MutationCarcinoma, Pancreatic DuctalAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansFemaleMaleAgedMiddle AgedAdultAged, 80 and overNeoplasm MetastasisPiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

HRS-4642KRAS G12Dadebrelimabpancreatic cancertargeted therapy

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntibodies, Monoclonal, HumanizedsotorasibPiperazinesPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Pancreatic Cancer Institute, Shan…
  • Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.

Zitieren

APA

Shi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026). Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Cancer Cell, 44(10), 2100-2107.e2. https://doi.org/10.1016/j.ccell.2026.08.012

Vancouver

Shi S, Wei M, Du N, Li J, Han B, Wang W, et al. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. Cancer Cell. 2026;44(10):2100-2107.e2. doi:10.1016/j.ccell.2026.08.012

BibTeX
@article{Shi2026,
  author = {Shi, Si and Wei, Miaoyan and Du, Nan and Li, Jialin and Han, Boyue and Wang, Wei and Hu, Xin and Luo, Fei and Xu, Jin and Yu, Xianjun},
  title = {Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {10},
  pages = {2100--2107.e2},
  doi = {10.1016/j.ccell.2026.08.012}
}
Kostenlos starten →